Nasdaq
$61.23▼ 0.02%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $8.30BShares out 1.400M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
33- 4d agoAfter-hours26.10.21 05:364Ownership#●●●
CYTOKINETICS INC
Nancy Wysenski, an executive at Cytokinetics, reported a change in her beneficial ownership of company securities as of October 16, 2026. This filing serves as a standard disclosure regarding the executive's stock holdings.…more
$61.23-0.02%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 4d agoAfter-hours26.10.21 05:354Ownership
CYTOKINETICS INC
Director Edward M. Kaye of Cytokinetics, Inc. filed a Form 4 on October 20, 2026, reporting changes in beneficial ownership of securities as of October 16, 2026. This filing serves as a standard disclosure of insider equity activity.…more
$61.23-0.02%vs prev closeView filingShare - 4d agoAfter-hours26.10.21 05:334Ownership
CYTOKINETICS INC
Director Robert Arthur Harrington of Cytokinetics reported a transaction involving company securities on October 16, 2026, via SEC Form 4. This filing formalizes the change in insider holdings and provides transparency regarding the company's internal ownership structure.…more
$61.23-0.02%vs prev closeView filingShare
32 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoAfter-hours26.10.22 05:00#●●●
Cytokinetics to Report Third Quarter 2026 Results on November 4
Cytokinetics announced it will report its third quarter 2026 financial results on November 4, 2026, after market close. Management will host a conference call following the release to discuss financial performance and provide business updates.…more
$61.23-0.02%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 5d agoAfter-hours26.10.20 05:00
●●●●●●●● ●●●●● ●●●●●●
Cytokinetics has granted stock options and restricted stock units to 29 new employees as a material inducement for their employment. This is a standard compensation practice and does not represent a material change in the company's financial position.…more
$61.23-0.02%vs prev close - 6d agoPre-market26.10.19 20:30
●●●●●●●● ●●●●● ●●●●●●
Cytokinetics announced that Health Canada has approved MYQORZO for the treatment of symptomatic obstructive hypertrophic cardiomyopathy. This marks the fifth regulatory approval for the drug in less than a year, supporting the company's global commercialization efforts.…more
$61.23-0.02%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report